Dogwood Therapeutics (NASDAQ:DWTX) Posts Quarterly Earnings Results, Misses Estimates By $4.80 EPS

Dogwood Therapeutics (NASDAQ:DWTX) announced its earnings results on Monday. The company reported ($6.29) earnings per share for the quarter, missing analysts’ consensus estimates of ($1.49) by ($4.80), Zacks reports.

Dogwood Therapeutics Stock Performance

Shares of Dogwood Therapeutics stock opened at $5.01 on Tuesday. The company has a market capitalization of $6.67 million, a PE ratio of -0.76 and a beta of 2.07. Dogwood Therapeutics has a 52-week low of $1.62 and a 52-week high of $29.28. The company has a 50-day simple moving average of $7.73.

Dogwood Therapeutics Company Profile

Dogwood Therapeutics, Inc is a development-stage biotechnology company, which engages in developing therapeutics for pain and fatigue illness. Its product includes Halneuron. It focuses on antiviral therapies IMC-1 and IMC-2 to treat diseases associated with a viral triggered abnormal immune response such as Long-COVID and fibromyalgia.